- Update of a phase II, multicenter clinical trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.Yan, Jin; Han, Yunwei; Zhang, Li; Jin, Yongdong; Sun, HaoAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancerWang, F.; Xiao, J.; Zhang, Y.; Yuan, X.; He, M.; Fang, W.; Zhang, Y.; Wang, W.; Hu, X.; Ma, Z.; Yao, Y.; Zhuang, Z.; Zhou, F.; Ying, J.; Yuan, Y.; Zou, Q.; Guo, Z.; Wu, X.; Jin, Y.; Mai, Z.; Guo, Y.; Xu, R.ESMO 24th World Congress on Gastrointestinal Cancer, Barcelona, SPAIN, 2022-06-29 To 2022.
- Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.Yan, Jin; Han, Yunwei; Zhang, Li; Jin, Yongdong; Sun, HaoGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.
会议论文
A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer
9阅读
